Re: Stopeck A, Rader M, Henry D, et al. Cost-effectiveness of denosumab vs. zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

Journal of Medical Economics; December 5, 2012 [Letter to the Editor]

View abstract

Authors

Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M